Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Zachary Richard Hunter, Ph.D.

Co-Author

This page shows the publications co-authored by Zachary Hunter and Bryan Ciccarelli.
Connection Strength

0.628
  1. Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):241-3.
    View in: PubMed
    Score: 0.133
  2. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):160-3.
    View in: PubMed
    Score: 0.115
  3. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica. 2010 Mar; 95(3):470-5.
    View in: PubMed
    Score: 0.105
  4. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma. 2011 Sep; 52(9):1777-86.
    View in: PubMed
    Score: 0.029
  5. Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):172-5.
    View in: PubMed
    Score: 0.029
  6. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):152-6.
    View in: PubMed
    Score: 0.029
  7. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5.
    View in: PubMed
    Score: 0.025
  8. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34.
    View in: PubMed
    Score: 0.025
  9. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7.
    View in: PubMed
    Score: 0.024
  10. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85.
    View in: PubMed
    Score: 0.024
  11. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9.
    View in: PubMed
    Score: 0.023
  12. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
    View in: PubMed
    Score: 0.023
  13. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
    View in: PubMed
    Score: 0.023
  14. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 01; 110(7):2561-4.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.